PriceTargets.com logo

Definium Therapeutics - DFTX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $35.22
  • Forecasted Upside: 93.21%
  • Number of Analysts: 12
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 9 Buy Ratings
  • 2 Strong Buy Ratings
$18.23 As of 02/2/2026 05:00 PM ET
▲ +1.35 (8.00%)

This chart shows the closing price for DFTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Definium Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DFTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DFTX

Analyst Price Target is $35.22
▲ +93.21% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Definium Therapeutics in the last 3 months. The average price target is $35.22, with a high forecast of $61.00 and a low forecast of $20.00. The average price target represents a 93.21% upside from the last price of $18.23.

This chart shows the closing price for DFTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 12 investment analysts is to buy stock in Definium Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 2 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/10/2024
  • 3 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/8/2024
  • 3 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/6/2025
  • 2 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/7/2025
  • 2 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/5/2025
  • 2 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/3/2025
  • 3 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
1/2/2026
  • 3 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
2/1/2026

Latest Recommendations

  • 2 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
2/2/2026Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight
1/29/2026Jefferies Financial GroupInitiated CoverageBuy$30.00
1/29/2026Robert W. BairdSet Target$37.00
1/29/2026Jefferies Financial GroupInitiated CoverageBuy$30.00
1/23/2026Royal Bank Of CanadaBoost TargetOutperform ➝ Outperform$20.00 ➝ $36.00
1/22/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
1/5/2026Needham & Company LLCReiterated RatingBuy ➝ Buy
12/23/2025Jones TradingInitiated CoverageBuy$61.00
11/19/2025Chardan CapitalUpgradeStrong-Buy
11/7/2025Canaccord Genuity GroupBoost TargetBuy ➝ Buy$16.00 ➝ $25.00
11/7/2025Royal Bank Of CanadaLower TargetOutperform ➝ Outperform$21.00 ➝ $20.00
10/14/2025Lifesci CapitalUpgradeStrong-Buy
10/13/2025Needham & Company LLCSet TargetBuy$28.00
10/13/2025Needham & Company LLCInitiated CoverageBuy$28.00
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
8/4/2025OppenheimerInitiated CoverageOutperform$25.00
8/1/2025Chardan CapitalReiterated RatingBuy ➝ Buy$20.00
5/13/2025Cantor FitzgeraldUpgradeStrong-Buy
5/9/2025Chardan CapitalReiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
3/7/2025Robert W. BairdLower TargetOutperform ➝ Outperform$27.00 ➝ $16.00
3/7/2025HC WainwrightReiterated RatingBuy ➝ Buy$55.00 ➝ $55.00
1/31/2025HC WainwrightReiterated RatingBuy ➝ Buy$55.00 ➝ $55.00
1/28/2025Evercore ISIInitiated CoverageOutperform$23.00
12/20/2024Chardan CapitalInitiated CoverageBuy$20.00
12/17/2024OppenheimerReiterated RatingOutperform ➝ Outperform$20.00 ➝ $20.00
11/11/2024HC WainwrightReiterated RatingBuy ➝ Buy$55.00 ➝ $55.00
10/14/2024Leerink PartnersInitiated CoverageOutperform$20.00
10/11/2024Leerink PartnersUpgradeStrong-Buy
9/16/2024Canaccord Genuity GroupLower TargetBuy ➝ Buy$16.00 ➝ $14.00
8/29/2024HC WainwrightBoost TargetBuy ➝ Buy$35.00 ➝ $55.00
7/31/2024HC WainwrightReiterated RatingBuy ➝ Buy$35.00 ➝ $35.00
7/24/2024Roth MkmUpgradeStrong-Buy
7/24/2024Roth MkmInitiated CoverageBuy ➝ Buy$36.00 ➝ $36.00
6/21/2024Cantor FitzgeraldReiterated RatingOverweight
6/5/2024Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform$22.00 ➝ $22.00
5/29/2024Robert W. BairdUpgradeStrong-Buy
5/28/2024Robert W. BairdInitiated CoverageOutperform$27.00
5/24/2024HC WainwrightReiterated RatingBuy ➝ Buy$35.00 ➝ $35.00
5/13/2024OppenheimerReiterated RatingOutperform ➝ Outperform$29.00 ➝ $20.00
5/10/2024HC WainwrightLower TargetBuy ➝ Buy$75.00 ➝ $35.00
4/15/2024Leerink PartnersReiterated RatingOutperform
4/15/2024Leerink PartnersInitiated CoverageOutperform$20.00
3/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$75.00
3/1/2024HC WainwrightReiterated RatingBuy ➝ Buy$75.00
2/29/2024Royal Bank Of CanadaBoost TargetOutperform ➝ Outperform$14.00 ➝ $15.00
12/5/2023Canaccord Genuity GroupInitiated CoverageBuy$9.00
10/23/2023Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform$7.00
8/22/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$7.00
8/4/2023HC WainwrightReiterated RatingBuy$75.00
8/4/2023Royal Bank Of CanadaBoost TargetOutperform ➝ Outperform$5.00 ➝ $7.00
4/14/2023EF Hutton Acquisition Co. IReiterated RatingBuy$21.00
4/14/2023OppenheimerReiterated RatingOutperform$22.00
3/16/2023HC WainwrightReiterated RatingBuy$75.00
3/10/2023EF Hutton Acquisition Co. IReiterated RatingBuy$21.00
3/10/2023Royal Bank Of CanadaReiterated RatingOutperform$5.00
1/19/2023HC WainwrightReiterated RatingBuy$75.00
12/16/2022EF Hutton Acquisition Co. IInitiated CoverageBuy$21.00
12/15/2022UBS GroupInitiated CoverageBuy$21.00
12/9/2022Roth MkmReiterated RatingBuy$25.00
11/21/2022Canaccord Genuity GroupLower Target$22.00 ➝ $18.00
11/16/2022Royal Bank Of CanadaInitiated CoverageOutperform
11/14/2022Maxim GroupLower Target$22.50 ➝ $8.00
10/4/2022Canaccord Genuity GroupLower TargetBuy$60.00 ➝ $22.00
9/21/2022HC WainwrightBoost TargetBuy$75.00
8/30/2022OppenheimerBoost Target$3.50 ➝ $52.00
8/25/2022OppenheimerInitiated CoverageOutperform
8/16/2022HC WainwrightLower TargetBuy$150.00 ➝ $75.00
8/10/2022Cantor FitzgeraldInitiated CoverageOverweight$45.00
5/23/2022HC WainwrightReiterated RatingBuy$150.00
5/4/2022Roth MkmInitiated CoverageBuy$105.00
8/5/2021HC WainwrightInitiated CoverageBuy$150.00
6/28/2021Maxim GroupInitiated CoverageBuy$90.00
(Data available from 2/2/2021 forward)

News Sentiment Rating

0.46 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 8 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 6 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
8/6/2025
  • 11 very positive mentions
  • 6 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2025
  • 7 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
10/5/2025
  • 8 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 7 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025
  • 13 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/3/2026
  • 4 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/2/2026

Current Sentiment

  • 4 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Definium Therapeutics logo
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
Read More

Today's Range

Now: $18.23
Low: $16.79
High: $18.70

50 Day Range

MA: $13.76
Low: $11.75
High: $17.48

52 Week Range

Now: $18.23
Low: $4.70
High: $18.70

Volume

2,053,240 shs

Average Volume

2,260,137 shs

Market Capitalization

$1.80 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.57

Frequently Asked Questions

What sell-side analysts currently cover shares of Definium Therapeutics?

The following Wall Street research analysts have issued stock ratings on Definium Therapeutics in the last year: Canaccord Genuity Group Inc., Cantor Fitzgerald, Chardan Capital, HC Wainwright, Jefferies Financial Group Inc., Jones Trading, Lifesci Capital, Needham & Company LLC, Oppenheimer Holdings, Inc., Robert W. Baird, Royal Bank Of Canada, and Weiss Ratings.
View the latest analyst ratings for DFTX.

What is the current price target for Definium Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Definium Therapeutics in the last year. Their average twelve-month price target is $35.22, suggesting a possible upside of 93.2%. Jones Trading has the highest price target set, predicting DFTX will reach $61.00 in the next twelve months. Chardan Capital has the lowest price target set, forecasting a price of $20.00 for Definium Therapeutics in the next year.
View the latest price targets for DFTX.

What is the current consensus analyst rating for Definium Therapeutics?

Definium Therapeutics currently has 1 sell rating, 9 buy ratings and 2 strong buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe DFTX will outperform the market and that investors should add to their positions of Definium Therapeutics.
View the latest ratings for DFTX.

What other companies compete with Definium Therapeutics?

Other companies that are similar to Definium Therapeutics include Hims & Hers Health, Option Care Health, RadNet, PACS Group and Sotera Health. Learn More about companies similar to Definium Therapeutics.

How do I contact Definium Therapeutics' investor relations team?

Definium Therapeutics' physical mailing address is One World Trade Center Suite 8500 New York, NY 10007 United States. The company's listed phone number is 212 220 6633 and its investor relations email address is [email protected]. The official website for Definium Therapeutics is definiumtx.com. Learn More about contacing Definium Therapeutics investor relations.